The HALP Index as a Bridge Between Nutrition, Inflammation, and Coagulation in Predicting DVT Risk in Stroke Patients

Siqi Zhang1,2, Shuangyang Niu1,2, Yonghui Wang2

  • 1School of Nursing and Rehabilitation, Shandong University, Jinan, China.

PubMed

The hemoglobin-albumin-lymphocyte-platelet (HALP) index, a composite marker reflecting nutritional, inflammatory, and immune status, has been linked to various health outcomes. However, its role in predicting deep vein thrombosis (DVT) occurrence in stroke patients and its potential influence on coagulation biomarkers, particularly D-dimer, remain poorly understood. This study aims to investigate the association between the HALP index and the occurrence of DVT in stroke patients, exploring the potential moderating role of HALP in regulating D-dimer levels and DVT formation. A retrospective study was conducted with 611 stroke patients, categorized into quartiles based on HALP scores. Multivariate logistic regression, restricted cubic spline (RCS) analysis, and subgroup analyses stratified by age, gender, body mass index (BMI), and D-dimer levels were performed to assess the relationship between HALP and DVT. Moderation analysis was used to explore the regulatory effect of HALP on D-dimer levels. HALP levels were inversely associated with DVT occurrence. Patients in higher HALP quartiles (Q3: 33.40-47.93, Q4: 47.93-152.58) exhibited significantly lower odds of DVT (p < .001). RCS modeling identified a threshold effect, with a sharp increase in DVT occurrence below a HALP level of 33.5. Subgroup analyses revealed that the protective association of higher HALP scores with reduced DVT incidence was consistent across all age groups and was significant in patients with both low and high D-dimer levels. This protective association was particularly strong in males (OR = 0.148) and overweight patients (OR = 0.089). The interaction between HALP and D-dimer was significant (p < .001), with HALP moderating the association between D-dimer and DVT occurrence. HALP is a strong, independent predictor of post-stroke DVT and moderates the prothrombotic impact of D-dimer. As a low-cost, integrative marker, HALP offers clinical value for early DVT occurrence stratification and individualized prevention strategies in stroke patients.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
275
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
185
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K